Publication
Title
EORTC Early Clinical Studies Group early phase II trial of S-I in patients with advanced or metastatic colorectal cancer
Author
Abstract
Cancer of the colon and rectum is one of the most frequent malignancies both in the US and Europe. Standard palliative therapy is based on 5-fluorouracil/folinic acid combinations, with or without oxaliplatin or irinotecan, given intravenously, Oral medication has the advantage of greater patient convenience and acceptance and potential cost savings. S-1 is a new oral fluorinated pyrimidine derivative. In a nonrandomised phase II study, patients with advanced/metastatc colorectal cancer were treated with S-1 at 40 mg m(-2) b.i.d. for 28 consecutive days, repeated every 5 weeks, but by amendment the dose was reduced to 35 mg m-2 during the study because of a higher than expected number of severe adverse drug reactions. In total 47 patients with colorectal cancer were included. In the 37 evaluable patients there were nine partial responses (24%), 17 stable diseases (46%) and II patients had progressive disease (30%). Diarrhoea occurred frequently and was often severe: in the 40 and 35 mg m(-2) group, respectively, 38 and 35% of the patients experienced grade 3-4 diarrhoea. The other toxicites were limited and manageable. S-1 is active in advanced colorectal cancer, but in order to establish a safer dose the drug should be subject to further investigations. (C) 2003 Cancer Research UK.
Language
English
Source (journal)
The British journal of cancer. - London
Publication
London : 2003
ISSN
0007-0920
DOI
10.1038/SJ.BJC.6600781
Volume/pages
88 :5 (2003) , p. 648-653
ISI
000182035300002
Full text (Publisher's DOI)
Full text (open access)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identifier
Creation 03.01.2013
Last edited 03.09.2024
To cite this reference